GlaxoSmithKline are being taking to task over the mark-up on two of their products: Voltaren Osteo Gel and Voltaren Emugel, products used primarily to ease arthritis pain.
Both products contain exactly the same ingredients, but it appears consumers are paying an additional $9.66 to have a cap that is easier to open for those with arthritis.
The Arthritis Foundation wants to know why medication for its members costs more when it gets an easy-to-open cap? Photo: GSK website.
'Many consumers, including those with arthritis, struggle with opening items and while consumers are prepared to pay a premium for accessibility, the $9.66 in our view is exorbitant” said Arthritis New Zealand CEO Sandra Kirby.
'Accessible packaging is an ongoing issue for people with arthritis in New Zealand. Arthritis New Zealand commends GSK for recognising the issue.
'We encourage other companies to invest in accessible packaging as a good business practice, but urge them to be realistic about the additional costs”.
Arthritis New Zealand is working with the Packaging Council of New Zealand to encourage other companies to invest in accessible packaging as a good business practice.



2 comments
Simple
Posted on 02-04-2016 21:06 | By Towball
Obscene exploitation of people's basic needs and requirements, praying on vonourability calculated GREED.
Disgraceful
Posted on 02-04-2016 22:01 | By Captain Hottie
Wow, that is ironic, for a medicine that is primarily used for those with joint pain. But how come those wretched compulsory childproof caps don't cost more? I find them extremely hard to use and I don't have arthritis, just very small and weak girly hands. I tend to leave the caps loose, or decant into another container which surely defeats the purpose of them. We should have a CHOICE. Not every household includes small children.
Leave a Comment
You must be logged in to make a comment.